Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis
Clinical trial NCT02404350 · COMPLETED
Trial details
- NCT number
- NCT02404350
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-08-31
- Primary completion
- 2017-08-16
- Enrollment
- 997
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.